Real-world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adjuvant long-acting octreotide therapy may improve disease-free survival (DFS) and overall survival (OS) for patients with grade 2 pancreatic neuroendocrine tumors (PanNETs) after surgery. This real-world study suggests a potential benefit for high-risk patients.
Area Of Science
- Endocrinology
- Oncology
- Gastroenterology
Background
- Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) post-resection lacks robust evidence.
- Grade 2 PanNETs with high recurrence risk present a significant clinical challenge.
- Long-acting octreotide is a potential therapeutic option requiring validation.
Purpose Of The Study
- To evaluate the efficacy of adjuvant long-acting octreotide in patients with G2 PanNETs.
- To assess the impact on disease-free survival (DFS) and overall survival (OS) in a real-world setting.
- To identify patient subgroups who may benefit most from this adjuvant therapy.
Main Methods
- Retrospective analysis of 357 patients with nonmetastatic G2 PanNETs undergoing radical resection (2008-2020).
- Application of propensity score matching and inverse probability of treatment weight analysis to control for confounding factors.
- Kaplan-Meier survival analysis and multivariate analyses to compare outcomes between octreotide and control groups.
Main Results
- The octreotide group demonstrated significantly longer DFS and OS compared to the control group.
- Multivariate and propensity score matching analyses confirmed that adjuvant octreotide was associated with improved DFS and OS.
- Subgroup analysis indicated particular benefit in patients with lymph node metastasis or Ki-67 <10%.
Conclusions
- Adjuvant therapy with long-acting octreotide following radical resection of nonmetastatic G2 PanNETs shows potential for improved DFS and OS.
- Real-world data supports octreotide as a viable adjuvant treatment option for high-risk G2 PanNET patients.
- Further prospective studies are warranted to confirm these findings and optimize treatment strategies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.